ETF·NYSE
State Street SPDR S&P Biotech ETF (XBI)
- Net assets
- $11.40B
- Expense ratio
- 0.35%
- Yield
- 0.35%
- 52-week range
- $106.30 $169.89
The short version
Where XBI stands today, in four lines, and what CleaRank Financial AI makes of it.
XBI at a glance
State Street SPDR S&P Biotech ETF (XBI): Hold, 51/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 200-day but below its 50-day moving average ($140.16 and $157.96).
- Fund Expense ratio 0.35%, $11.4B in net assets, +58.1% total return over 1 year.
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates State Street SPDR S&P Biotech ETF (XBI) Hold, with a model score of 51/100.
One-year performance lifts the score most: the price rose 33.74% over the past year. Momentum holds it back most: the 14-day RSI of 35.9 is in the bearish zone and the MACD line is negative. The trend is mixed: XBI trades 8.64% below its 50-day average of $157.96 and 2.97% above its 200-day average of $140.16.
Only on CleaRank
Figures we compute ourselves from XBI's own price history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
3/4Price above its 50-day average ›
The price of $144.32 is 8.6% below the 50-day simple moving average of $157.96.Price above its 200-day average ›
The price is 3.0% above the 200-day simple moving average of $140.16.50-day average above the 200-day ›
The 50-day average ($157.96) is 12.7% above the 200-day average ($140.16), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 60% of its 52-week range, between $106.30 and $169.89.
XBI share price
Pick a period: each tab shows how far XBI has moved over it, to the last close.
Today's trading
Where XBI sits inside today's range and its 52-week range.
Fund facts and valuation
What the fund holds, what it costs and how it is valued.
Fund checks
3/5Expense ratio at or below 0.20% ›
The fund charges 0.35% a year, $35.00 on a $10,000 holding.Over $1B in net assets ›
Net assets total $11.4B.No sector above 35% of the fund ›
The largest sector, Healthcare, makes up 99.3% of the fund.Pays a distribution ›
The distribution yield is 0.35%.Positive return over one year ›
The fund family reports a one-year total return of 58.06%.
XBI Fund Facts
State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security.
Sector weights
Trailing total returns
| Period | XBI |
|---|---|
| YTD | 29.42% |
| 1 month | -2.99% |
| 3 months | -0.32% |
| 1 year | 58.06% |
| 3 years | 29.50% |
| 5 years | 4.77% |
| 10 years | 9.21% |
As of Oct 17, 2026, XBI has an expense ratio of 0.35%, $11.40B in net assets and a distribution yield of 0.35%.
Fund reference data as of Oct 17, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change.
Key statistics
The headline figures for XBI.
What the numbers say
CleaRank Financial AI's reading of XBI's holdings, performance and risks.
State Street SPDR S&P Biotech ETF (XBI) is concentrated in Healthcare, which makes up 99.3% of the fund. Financial Services is a distant second at 0.7%. Because one sector accounts for nearly the entire portfolio, XBI moves almost in step with that sector. The fund is classified as Health, is run by State Street Investment Management, and was launched on January 31, 2006.
Costs are modest. The expense ratio is 0.35%, or $35.00 a year on a $10,000 holding. The fund's net assets total $11.4B, and its distribution yield is also 0.35%. Portfolio turnover stands at 71%.
On a typical day the price of XBI shifts by 1.82%, the 30-day standard deviation of its daily returns. Concentration matters here: Healthcare makes up 99.3% of the fund, so a setback in that sector would weigh on the whole. The price is 15.05% below its 52-week high of $169.89.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 35.9, showing bearish momentum without being oversold.RSI above 50 ›
An RSI of 35.9 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank AI analysis of XBI
The score, the reasoning behind it, and what could move the price next.
At $144.32, XBI is 2.97% above its 200-day average of $140.16 but 8.64% below its 50-day average of $157.96, so the price sits between the two moving averages. The 50-day average is 12.70% above the 200-day average, and that gap would shrink if the price keeps trading under the shorter average. Across the 52-week range, the price stands at 60%, with the low at $106.30 and the high at $169.89.
A recent pullback sits inside a stronger longer record: the price fell 6.40% over the past month, fell 6.44% over the past three months and rose 33.74% over the past year. On momentum, the 14-day RSI reads 35.9, in the bearish zone, above the oversold line, with the MACD line negative.
- Keep an eye on the two closest levels: the 20-day EMA at $152.22 sits above the price, and the 200-day SMA at $140.16 sits below it.
- A 14-day RSI of 35.9 is in the bearish zone, and the MACD line is negative. Readings above 70 or below 30 signal stretched momentum.
- Costs compound: at 0.35% a year, XBI charges $35.00 on every $10,000 invested.
The trend is mixed: XBI is above its 200-day average at $140.16 but below its 50-day average at $157.96. A close above the 50-day would turn both signals up, and a close below the 200-day would turn both down. In the meantime the price sits between the 200-day SMA ($140.16) underneath and the 20-day EMA ($152.22) overhead.
XBI's RSI is in the bearish zone, a reading that makes a fast rebound less likely.
Technical indicators
Momentum and trend for XBI, from its daily closes.
As of October 17, 2026, with XBI at $144.32, its 14-day RSI is 35.9 (showing bearish momentum without being oversold), its 50-day simple moving average is $157.96 and its 200-day is $140.16.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What XBI moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, XBI's 1-year correlation of daily returns is +0.57 with S&P 500 (SPY), +0.53 with Nasdaq 100 (QQQ), +0.30 with Bitcoin (BTC) and +0.22 with gold (XAU).
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
XBI trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from XBI's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much XBI tends to move, against the market and on its own.
The long record
XBI's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.82% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 62.1%, from February 2021 to October 2023; the price is still 15.5% below that peak.Most 1-year holds ended higher ›
61% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $24,774, against $42,055 in the S&P 500 (SPY).
XBI Drawdowns & Recovery
As of October 17, 2026, XBI's worst peak-to-trough fall over the last 10 years with dividends reinvested was -62.1% (February 2021 to October 2023); it is still 15.5% below that peak, and 61% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into XBI in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: XBI trailed the S&P 500 over this period: $24,774 against $42,055.
A $10,000 investment in XBI in October 2016 would be worth about $24,774 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to XBI, and which have not.
Strongest month, June: an average of +6.92%, up in 9 of 10 years.
Weakest month, March: an average of -3.82%, up in 1 of 10 years.
This month, October: has averaged -0.25%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, XBI's strongest calendar month has been June (average +6.92%, up in 9 of 10 years) and its weakest March (average -3.82%, up in 1 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in XBI, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in XBI today could grow to about $20,637 by 2036 in the base case, with a 90th-percentile outcome near $75,370 and a 10th-percentile outcome around $5,650. The simulation models price only; at today's 0.35% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
XBI 2030 Scenarios (Monte Carlo)
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $193 for XBI by 2030 in the base case, from $144 today (1.3x over 4 years). The 10th-percentile path ends near $84.99. These are outcomes of a Monte Carlo simulation run on XBI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $103 | $155 | $234 | |
| 2028 | $93.47 | $167 | $298 | |
| 2029 | $88.22 | $179 | $365 | |
| 2030 | $84.99 | $193 | $437 | |
| 2031 | $82.96 | $207 | $518 |
Method: a lognormal simulation of XBI's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Questions people ask
Answered from the figures on this page, as of October 17, 2026.